Thermo Fisher Q2 FY26 GAAP diluted EPS rises 9% to $4.68; revenue increases 10% to $11.99 billion

Thermo Fisher Scientific Inc.

TMO

0.00

Thermo Fisher posted Q2 2026 revenue up 10% to USD 11.99 billion, including 5% organic growth.
GAAP diluted EPS rose 9% to USD 4.68; adjusted EPS climbed 13% to USD 6.03.
GAAP operating income increased 14% to USD 2.09 billion; operating margin widened 0.5 percentage points to 17.4%.
Adjusted operating income grew 15% to USD 2.73 billion; adjusted operating margin widened 0.9 percentage points to 22.8%.
Repurchased USD 1 billion of stock; announced divestiture of its microbiology business as customer activity continued to strengthen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607230600BIZWIRE_USPR_____20260723_BW352855) on July 23, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.